Cellebrite DI (CLBT) Projected to Post Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of $0.0940 per share and revenue of $145.83 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $12.70 on Tuesday. The stock’s 50-day moving average is $11.59 and its 200-day moving average is $13.30. The company has a market cap of $3.17 billion, a price-to-earnings ratio of 44.39, a price-to-earnings-growth ratio of 1.91 and a beta of 1.06. Cellebrite DI has a 12 month low of $9.58 and a 12 month high of $19.98.

Insider Buying and Selling

In related news, CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88. Following the sale, the executive directly owned 427,128 shares in the company, valued at approximately $4,800,918.72. This trade represents a 2.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO David Barter sold 12,134 shares of the firm’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $11.21, for a total value of $136,022.14. Following the sale, the chief financial officer owned 322,085 shares in the company, valued at approximately $3,610,572.85. The trade was a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 196,870 shares of company stock worth $2,797,143 over the last three months. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Lake Street Capital decreased their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. JPMorgan Chase & Co. cut their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. DA Davidson reaffirmed a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Finally, Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems.

The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian.